Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients

Journal of Thoracic Oncology

Volumn 5, Issue 3, 2010, Pages 376-379

  Wu, Chieh Hung ^a   Fan, Wen Chien ^a   Chen, Yuh Min ^a,b   Chou, Kun Ta ^a   Shih, Jen Fu ^a,b   Tsai, Chun Ming ^a,b   Lee, Yu Chin ^a,b   Perng, Ruery Perng ^a  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Elderly; Gefitinib; Non small cell lung cancer; Salvage therapy

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; IFOSFAMIDE; NAVELBINE; PROTEIN TYROSINE KINASE; UFT;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GROUPS BY AGE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SECOND LINE THERAPY; SURVIVAL TIME; TREATMENT RESPONSE; VOMITING;

EID: 77649322365     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181cee2d4     Document Type: Article

References (21)

1. Schottenfeld D. Etiology and epidemiology of lung cancer. In HI Pass, JB Mitchell, DH Johnson, et al. Lung Cancer: Principles and Practice. Philadelphia, PA: Lippincott Williams & Wilkins, 2000. Pp. 367-388.
2. Lee-Chiong TL Jr, Matthay RA. Lung cancer in the elderly patient. Clin Chest Med 1993;14:453-478.
3. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2085-2103.
4. Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353:123-132.
5. Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008;26:4233-4235.
6. Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-1818.
7. Chen YM, Perng RP, Tsai CM, et al. A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Lung Cancer 2006;52:333-338.
8. Chen YM, Tsai CM, Perng RP. Clinical experience with single-agent gemcitabine chemotherapy in patients with non-small-cell lung cancer in whom previous chemotherapy has failed. J Chin Med Assoc 2005;68:163-166.
9. Chou KT, Chen YM, Shih JF, et al. Phase II randomized study of weekly docetaxel alone or plus UFUR treatment in non-small cell lung cancer patients who failed previous chemotherapy. Lung Cancer 2008;59:64-68.
10. Chen YM, Perng RP, Tsai CM. Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: a prospective phase II study. J Chemother 2005;17:679-684.
11. Chen YM, Shih JF, Perng RP, et al. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 2006;129:1031-1038.
12. Chen YM, Liu JM, Chou TY, et al. Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy. Cancer 2007;109:1821-1828.
13. Chen YM, Perng RP, Lin WC, et al. Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Am J Clin Oncol 2002;25:509-512.
14. Chen YM, Shih JF, Lee CS, et al. Phase II study of docetaxel and ifosfamide combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy with or without paclitaxel. Lung Cancer 2003;39:209-214.
15. Chen YM, Perng RP, Lee CS, et al. Phase II study of gemcitabine and vinorelbine combination chemotherapy in patients with non-small-cell lung cancer not responding to previous chemotherapy. Am J Clin Oncol 2003;26:567-570.
16. Common Terminology Criteria for Adverse Events (CTCAE) v3.0 (NCI/CTEP web site). Available at: https:webapps.ctep.nci.nih.gov/ webobjs/ctc/webhelp/ welcome-to-ctcae.htm. Accessed July 15, 2009.
17. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
18. Kuo C-W, Chen Y-M, Chao J-Y, et al. Non-small cell lung cancer in very young and very old patients. Chest 2000;117:354-357.
19. Chen YM, Perng RP, Shih JF, et al. Chemotherapy for non-small cell lung cancer in elderly patients. Chest 2005;128:132-139.
20. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. The Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 1999;91:66-72.
21. Crinò L, Cappuzzo F, Zatloukal P, et al. Gefitnib versus vinorelbine in chemotherapy-naïve elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol 2008;26: 4253-4260.